Clinical trials
Observational Drug Hypersensitivity trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
29 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2020 | 4 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Recruiting | 6 |
| Unknown status | 3 |
| Terminated | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University Hospital, Montpellier | 5 |
| Chulalongkorn University | 4 |
| Albany Medical College | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Central Hospital, Nancy, France | 1 |
| Deraya University | 1 |
| KU Leuven | 1 |
| Lumicell, Inc. | 1 |
| Nationwide Children's Hospital | 1 |
| Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Drug Hypersensitivity | 29 |
| Hypersensitivity | 7 |
| Anaphylaxis | 4 |
| Drug-Related Side Effects and Adverse Reactions | 4 |
| Drug Hypersensitivity Syndrome | 3 |
| Stevens-Johnson Syndrome | 2 |
| Acute Generalized Exanthematous Pustulosis | 1 |
| Breast Neoplasms | 1 |
| Chronic Urticaria | 1 |
| Drug Eruptions | 1 |
Trials
Showing 26 to 29 of 29. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.